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Abstract: Oseltamivir is a common therapy against influenza A virus (IAV) infections. The acquisition
of oseltamivir resistance (OR) mutations, such as H275Y, hampers viral fitness. However, OR H1N1
viruses have demonstrated the ability to spread throughout different populations. The objective of
this work was to compare the fitness of two strains of OR (R6 and R7) containing the H275Y mutation,
and a wild-type (F) pandemic influenza A (H1N1) 2009 (pdm09) virus both in vitro and in vivo in
mice and to select one OR strain for a comparison with F in ferrets. R6 showed faster replication and
pathogenicity than R7 in vitro and in mice. Subsequently, R6 was selected for the fitness comparison
with the F strain in ferrets. Ferrets infected with the F virus showed more severe clinical signs,
histopathological lung lesions, and viral quantification when compared to OR R6-infected animals.
More importantly, differential viral kinetics correlated with differential pro-inflammatory host immune
responses in the lungs of infected ferrets, where OR-infected animals developed a protective higher
expression of type I IFN and Retinoid acid Inducible Gene I (RIG-I) genes early after infection, resulting in
the development of milder disease. These results suggest the presence of early specific viral-host immune
interactions relevant in the development of influenza-associated lung pathology.
Keywords: influenza; immunopathology; pneumonia; pH1N1; resistance; oseltamivir
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1. Introduction
The pandemic A (H1N1) 2009 virus (referred to hereafter as pdm09) caused the first influenza A
virus (IAV) pandemic of the 21th century. Currently, the pdm09 virus causes a predominantly mild
disease, but it develops into severe lung pathology associated with mortality in some cases [1]. The pdm09
matrix protein (MP) gene came from the Eurasian swine lineage [2], which contains the S31N mutation
conferring resistance to adamantine antiviral therapeutics [3]. Therefore, the pharmacological therapy
against pdm09 infection depends on neuraminidase inhibitor (NAIs) antivirals, namely oseltamivir
and zanamivir [3,4]. A single amino acid substitution at several positions in or around the NA
active site is able to strengthen virus resistance against NAIs [5]. Among such NA substitutions,
a histidine-to-tyrosine substitution at position 275 (H275Y) is one of the best-characterized and most
commonly found oseltamivir-resistant (OR) mutations [6–8].
In general, it is considered that resistant mutations in the NA enzymatic position compromise viral
fitness [9,10], as NAI-resistant viruses have been associated with deficient viral replication and spread in
seasonal H1N1 and H3N2 strains [11,12]. However, seasonal H1N1 with the H275Y mutation emerged
and expanded globally without oseltamivir selection [13]. Such an event demonstrated that viral
fitness was no longer compromised by the resistance mutation. Several investigations have revealed
the presence of diverse “permissive” mutations (R222Q, V234M, and possibly D354G) in seasonal and
pdm09 viruses that allowed the addition of H275Y without compromising viral fitness [14–16].
Overall, OR pdm09 viral infections have generally been described in immunocompromised
patients who have been subjected to antiviral treatment [17–19]. Regardless, community clusters of OR
pdm09 viruses containing the H275Y mutation have been reported [20–23]. Despite the fact that the
frequency of OR in pdm09 viruses has remained low (<2%) [24–27], there are indicators which suggest
that pdm09 could permanently acquire the NA H275Y mutation, as happened with its predecessor,
the seasonal H1N1 [10,23].
The aim of this study was to compare the virulence of two OR pdm09 strains (R6 and R7) and a
wild-type (Wt) virus (F) in vitro and in mice, and to characterize differential innate viral-host immune
parameters associated with viral pathogenicity in ferrets as a human model of disease.
2. Materials and Methods
2.1. Oseltamivir-Resistant and Wild-Type Viruses
The three strains of human pdm09 viruses used in this study were isolated as previously
described [28]. The A/Baleares/RR6121/2009 and A/Madrid/RR7495/2011 viruses bear the OR H275Y
mutation and are hereafter referred to as R6 and R7, respectively. Both viruses were isolated from
immunocompromised patients. The virus A/CastillaLaMancha/RR5911/2009, referred to here as F,
was isolated from a fatal case of a patient without co-morbidities. Influenza viruses R6, R7, and F were
grown in a Madin–Darby canine kidney (MDCK), as previously described [28]. R6 and R7 viral titers
were 107.8 50% tissue culture infective dose (TCID50)/mL and 107.3 TCID50/mL, respectively. The F
virus had a titer of 106.02 TCID50/mL. Titers were determined using the Reed and Muench method [29].
Aminoacidic differences between viral strain-predicted proteins were identified. For each viral protein,
the frequency of the amino acid at the mutated positions was calculated over an alignment greater
than 1800 sequences of IAV recovered from the Global Initiative on Sharing Avian Influenza Data
(GISAID) database.
2.2. In Vitro Infection and Viral Load
MDCK cells were infected at 0.0001 multiplicity of infection (MOI) with OR pdm09 virus R6
and R7 and the Wt virus F. At 0, 6, 12, 24, and 48 h post-infection (hpi), supernatants were collected.
Viral quantification was determined by TCID50 and a plaque assay determining PFU as previously
described [28]. Virus infectivity in lung tissue samples from the mice virus was determined at 3, 5,
and 7 dpi, as described by Almansa and colleagues [30].
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In ferrets, viral secretion shedding in nasal swabs at 0, 1, 3, 6, and 10 dpi was determined by
PFU for all available infected animals, as described before [28]. Nasal swabs were placed in 0.5 mL
of DMEM (BioWhittaker®, Lonza, Verviers, Belgium) with 600 µg/mL penicillin and streptomycin,
and frozen at −80 ◦C until further processing.
2.3. Ethical Statement
Experiments with mice and ferrets were performed following the animal use protocol approved
by “Comissió d’Ètica en l’Experimentació Animal i Humana de la Universitat Autònoma de Barcelona”
(Internal Register Number: 1124M2R) and the Ethical Animal Experimentation Commission of
the Catalan Government (Register Number: 5767). Seven-week-old C57BL6/JOlaHsd (C57BL6)
female mice (Harlan Laboratories, Barcelona, Spain) were housed in groups in experimental isolation
cages at the biosafety level 3 (BSL3) facilities at the Centre de Recerca en Sanitat Animal (CReSA,
Barcelona, Spain). Once mice were separated into different groups, they were kept for one week
in acclimation. Animals were kept in standard housing cages and provided with commercial food
pellets and tap water ad libitum throughout the experiment. Between eight and nine months of age,
IAV seronegative ferrets (Euroferret, Denmark) were placed in BSL3 facilities at CReSA, in experimental
isolation rooms, and then acclimated for 6 days. The animals were inhabited in standard housing cages
for laboratory ferrets (F-SUITE Ferret Housing, Tecniplas, Italy) and were provided with commercial
food pellets and tap water ad libitum throughout the experiment.
2.3.1. Mice Infection, Clinical Signs, and Sampling
C57BL6/JOlaHsd female mice were separated into three groups of 20 animals. Mice were assigned
to the following three groups: Uninfected control group (C); R6-infected group (R6); and R7-infected
group (R7). Each virus was inoculated separately by an intranasal route at a dose of 104 PFU/mL.
The control group remained uninfected.
Mice were observed daily to record changes in body weight and clinical signs and any animal
presenting severe weight loss of more than 20% compared to the weight at the start of the experiment,
difficult labored breathing, or a prolonged inability to remain upright was humanely euthanized.
Specimens of the serum and lung were acquired at 0, 3, 5, 7, and 14 dpi. In order to minimize suffering,
blood samples were obtained under 5% isofluorane anesthesia. Euthanasia of mice was performed under
anesthesia with 5% isoflurane with an intraperitoneal inoculation of penthobarbital. Subsequently,
lungs were dissected by surgical methods. Lung tissues were weighed, homogenized, dry ice frozen,
and stored at −80 ◦C until further use.
2.3.2. Ferret Infection, Clinical Signs, and Sampling
Sixteen ferrets were randomly assigned to three different experimental groups. The control group
included three ferrets. The R6 and F group included eight ferrets each, intratracheally inoculated
with 105 TCID50/mL of the R6 or F pdm09 strain, respectively. Ferrets (Euroferret, Denmark) were
neutered males between eight and nine months old and seronegative for IAV (influenza A antibody
competition multi-species ELISA, ID Screen®, France). Intratracheal inoculation was performed under
deep sedation of the animals with ketamine (5–10 mg/kg) (Imalgene 1000® Merial, S.A., Spain) and
medetomidine (0.05 mg/kg) (Domtor® Pfiser, S.A., Spain), both administered subcutaneously, and after
inoculation, animals were reverted from anesthesia with atipemazol (0.25 mg/kg), administered
subcutaneously. Animals were monitored by a specialized veterinarian until they had fully recovered
from sedation.
Ferrets were monitored daily for clinical signs following a clinical score modified from [28].
Control animals’ clinical signs were monitored during acclimatization and at 0 dpi.
Animals were euthanized by an intravenous injection of sodium pentobarbital (100 mg/kg) under
anesthesia with ketamine (5–10 mg/kg/SC) (Imalgene 1000® Merial, S.A., Spain) and medetomidine
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(0.05 mg/kg/SC) (Domtor® Pfiser, S.A., Spain). Necropsies were performed on 1, 3, and 10 days post
infection (dpi).
Ferret Acute Phase Proteins
Ferret serum APP haptoglobin (Hp) and serum amyloid A (SAA) were measured and quantified by
an ELISA Haptoglobin Assay and Multispecies Serum Amyloid A Immunoassay, (Tridelta Development
Ltd., County Kildare, Ireland). Sera samples were taken under sedation of the animals with butorphanol
0.5 mg/kg administrated subcutaneously, from the cranial vena cava at 0 dpi in control animals and all
infected animals available at 0, 1, 3, 6, and 10 dpi. All samples were collected in 1 mL blood-heparine
tubes. Heparine blood samples were centrifugated at 3000 rpm for 10 min at 4 ◦C to separate plasma
samples. Plasma samples were store at −20 ◦C. Animals were individually monitored by a specialized
veterinarian until they had completely recovered from sedation. Sampling at 0 dpi in all animals was
performed while animals were anesthetized for viral inoculation, in order to minimize the handling
and anesthetic procedures in the animals.
Viral RNA Detection and IAV Antigen Expression and Quantification in Ferret Lungs
Viral RNA was extracted with the NucleoSpin® RNA Virus Kit (Macherey-Nagel, Düren, Germany),
following the manufacturer’s instructions, using a 5 mm square sample of the proximal mediastinic
right caudal lobe of each ferret. The IAV M gene was quantified by TaqMan one-step quantitative real
time RT-PCR (rRT-PCR) using primers, a probe, and the amplification conditions described in [31]
using Fast7500 equipment (Applied Biosystems, Foster City, CA, USA). Individual samples were run
in duplicate and each assay contained known positive and negative amplification controls that were
also run in duplicate. Threshold cycle (Ct) values ≤40 were considered positive for IAV.
The IAV antigen was also quantified in the lung by immunohistochemistry (IHC).
Fixed paraffin-embedded tissues were stained with a primary antibody against the influenza A
nucleoprotein and IAV antigen immune staining was quantified as previously described [32].
Ferret Innate Immune Gene Expression Profiles
The gene expressions of IFNα, IFNβ, IFNγ, TNFα, IL-6, IL-8, CXCL10, and RIG-I were detected
by two-step RT-PCR, as previously described [32].
2.3.3. Histopathology
Mice and ferret lung sections were taken for histological examination, according to standard
protocols, and stained with hematoxylin and eosin (HE) for examination under light microscopy.
Cross sections of each mouse’s right lung lobes were separately evaluated, and semiquantitative
assessments of IAV-associated microscopic lesions in the lungs were performed. The histopathological
scoring grades assigned were ranked as follows: 0 (no lesions); 1 (mild to moderate necrotizing
bronchiolitis); 2 (bronchointerstitial pneumonia characterized by necrotizing bronchiolitis and
inflammation of close surrounding alveoli); and 3 (necrotizing bronchiolitis and diffuse inflammation
of the alveolar parenchyma in the section). Microscopic lesion scores were assigned for each lobe,
and the means were used for the final histopathological score for each animal.
2.3.4. Hemagglutination Inhibition (HI) Assay
Antibodies against IAV were measured using an HI assay, as previously described [28].
Briefly, mice and ferret sera were treated overnight with four volumes of Receptor Destroying
Enzyme (RDE) (Sigma-Aldrich SA, Madrid, Spain) solution (100 U/mL) at 37 ◦C. Then, five volumes of
1.5% sodium citrate were added to serum samples and incubated for 30 min at 56 ◦C. Treated sera were
diluted 1:2 in PBS. Finally, sera were incubated for 1 h at 4 ◦C with 4 hemagglutination units of pdm09
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and one volume of a 50% suspension of RBC. Controls of positive and negative sera were added to the
assay. Positive results were considered when HI titers were >40.
2.4. Statistical Analyses
GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) was used to perform data visualization.
All statistical analysis was carried out using SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). For all
analyses, mice and ferrets were used as the experimental unit. The significance level (α) was
established at 0.05. The Shapiro Wilk and Levene’s test were used to evaluate the normality of the
distribution of the analysed quantitative variables and the homogeneity of variances, respectively.
A normal distribution was not detected for any continuous variable. Therefore, a non-parametric
test (Wilcoxon test) employing the U Mann–Whitney test to compare each pair of values was used to
confront the different values collected for all of the parameters (weight loss, clinical signs, acute phase
proteins, histopathology, viral load, and cytokine and viral sensing gene expression profiles) between
groups (control, F, and R6 and R7 influenza virus) at all time points.
3. Results
3.1. Oseltamivir-Sensitive (F) and Oseltamivir-Resistant (R6) Replicate Faster than the R7 Virus In Vitro
Viral replication kinetics for R6, R7, and F viruses were examined by a regular virological method
(PFU plaque assay and TCID50) and expressed in titers at different time points (Figure 1A,B). For PFU
plaque assay results, viral titers from R6-infected cells (2.4 × 105 PFU/mL) were similar to that for the F
virus (1.6 × 105 PFU/mL), but 24 times higher than the one from R7-infected cells (1 × 104 PFU/mL)
at 24 hpi (Figure 1A). No differences were observed at 48 hpi. When viral titers were measured by
the TCID50 assay (Figure 1B), the progeny from F virus was detected as early as 6 hpi, whereas the
one from the R6 virus was firstly detected at 12 hpi. At 24 hpi, higher viral titers were observed in F-
(106.8 TCID50/mL and R6- (106.9 TCID50/mL) infected cells when compared with R7 (105.8 TCID50/mL)
(Figure 1B). Viral production was undetectable before 24 hpi in R7-infected cells. However, both OR
viruses (R6 and R7) reached similar titers at 48 hpi, with values of 106.1 and 106.8 TCID50/mL, respectively.
In conclusion, the R6 virus seems to replicate faster than the R7 virus in vitro.
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Figure 1. In vitro virus kinetics of pdm09 OR viruses (R6 and R7) were compared with a non-resistance
pdm09 virus (F) and the viral titer was determined at 0, 6, 12, 24, and 48 h post-infection (hpi) by a
plaque assay (A) and by 50% tissue culture infective dose (TCID50) (B).
3.2. R6-Infected Mice Presented Earlier Clinical Signs and Higher Mortality Rates than R7-Infected Mice
C57BL6 mice were intranasally infected with 104 PFU of R6 or R7 viruses. The control group was
not subjected to intranasal inoculation, remaining untreated. Animals were monitored daily for two
weeks to control the body weight and survival (Figure 2A,B). Loss of body weight was not observed in
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untreated mice. The R6-infected group experienced a peak of weight loss at day 4 pi and R7-infected
mice showed a similar peak but thereafter, at day 7 pi. During the first 2 dpi, the R6-infected group
showed a statistically significant (p < 0.05) higher percentage of weight loss compared to R7-infected
mice. Both infected groups experienced a statistically significant higher percentage of weight loss from
days 3 to 7 pi compared to uninfected animals (p < 0.05). The statistical analysis of days 8 to 14 pi
did not show any differences within groups; however, it is important to emphasize that body weight
recovery was delayed in the R6-infected mice, whereas the R7 group started to exhibit an increased
body weight at 7 dpi (Figure 2A). Importantly, 40% lethality was observed in the R6 group of animals
at 4 dpi in comparison with 20% lethality for R7-infected mice. On the subsequent 2 dpi, lethality was
maintained in R6-infected mice at 40% lethality and R7-infected mice at 30%. From day 7 to 14 pi,
both infected groups exhibited 50% lethality (Figure 2B). All uninfected mice survived during the
course of the study. Additionally, the percentage of survival was statistically significant (p < 0.0001) in
control mice confronting the OR virus from day 4 pi until the end of the experimental infection course.
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Figure 2. Influence on body weight (A), survival (B), (C) virus load in lungs, and (D) antibody response
by haemagglutination inhibition (HI) in pdm09 oseltamivir resistance (OR)-infected mice. Groups of
20 mice were distributed as follows: Control group, R6-infected mice, and R7-infected mice. All values
are the mean ± SEM of one experiment. (B) shows the percentage of survival of R6- and R7-infected
groups. (C,D) exhibit individual values for each tested animal and the mean is represented by bars.
3.3. Virus Replication in Mice
Since lungs are primarily infected by IAV, samples of the target tissue from five infected mice were
used to det rmine vi al titers. At all time points, no statistically significant differences were obs rved
within infected groups (Figure 2C). The vir burden increased gradually in the lungs from 3 to 7 dpi
in R7 mice. Moreover, the lung viral load of R6-infected mic was reduced t 7 dpi and by 14 dpi,
no infectious virus was detectable in any infected mice.
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3.4. R6 and R7 Presented Similar Mice Antibody Responses
The antibody response to the R6 and R7 virus was determined by the HI assay. Sera from days
7 and 14 pi were tested. Uninfected control mice were seronegative throughout the study period.
At 7 dpi, the presence of hemagglutinin inhibiting antibodies was detected early in two mice from the
R6 group and three from the R7 group. There was an HI antibody response observed in both infected
groups against the virus used for infection in each group; however, few cross-reactive antibodies were
confirmed at 14 dpi (Figure 2D).
3.5. R6-Infected Mice Showed More Severe Histopathological Lesions than R7-Infected Mice
Mice infected with the R6 virus presented higher histopathological scores than R7-infected mice
(Figure 3A). Control animals did not present any histopathological lesions in the lungs at any time
point (Figure 3B). At 3 dpi, only one R7-infected animal presented histopathological lesions consistent
with mild necrotizing bronchiolitis, characterized by respiratory and glandular epithelial necrosis and
mild lymphoplasmacytic infiltration (Figure 3C). At 5 dpi, all R6-infected animals presented moderate
to severe bronchointerstitial pneumonia characterized by bronchi/bronchiolar and glandular necrosis
with lymphoplasmacytic inflammation and neutrophilic and macrophagic infiltration in the adjacent
alveoli (Figure 3D), whereas only three out of five R7-infected mice presented the same lesional score.
At 7 dpi, three in four R7-infected mice and one in two R6-infeceted mice presented bronchointerstitial
pneumonia. However, the low number of R6 mice examined at this time point may have lowered the
histopathological score in comparison to the R7 group. At 14 dpi, one R6-infected mouse presented
severe histopathological lesions consistent with bronchointerstitial pneumonia, while no R7-infected
animals showed lesions at this time point.
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Figure 3. Histopathology of lung lesions in mice. (A) Histopathologic scoring of lung tissues examined.
Individual values per animal with means represented by bars. (B) Control animals did not present
any histopathological lesions at any time point. At 3 dpi, only one R7-infected mouse presented
histopathological lesions consistent with bronchiolitis (C). At 5 dpi, all R6-infected mice presented with
severe broncho-interstitial pneumonia (D). Hematoxylin and eosin (HE) stain (10× objective field).
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3.6. A/Baleares/RR6121/2009 (R6), (A/Madrid/RR7495/2011) (R7), and A/CastillaLaMancha/RR5911/2009 (F)
Viruses Show Aminoacidic Differences
Viral sequences between F and R6 were compared and mutations PB2 225S, PB1 T20I, PB1 A652V,
PA K716E, PA L589I, and PA S594G were found. Recognized mutations were screened in the GISAID
database to detect the frequency in the pdm09 viruses (Table 1). Disparities in aminoacidic hallmarks
were identified in the following proteins: PB2, PB1, PA, NP, HA, NA, and NS1. Predominant mutations
fell into the viral polymerase complex proteins, especially into PB2 and PA. Notably, those in the
F virus were mostly exceptional in the pdm09 viruses (minimum of less than 2.5%). The R6 virus,
however, also showed some rare mutations with a frequency of 0.5%. The rest of the mutations were
distributed among the rest of the proteins and many of them were unusual in the R6 virus. One mutation
in the HA protein of the R6 virus is extremely rare (0.1%, just one sequence). Unfortunately, the domains
into which they fall have been roughly identified and the functional implication of those mutations has
not been previously recognized (apart from the oseltamivir resistance).
The R6 strain appeared more virulent than R7 and was selected for a comparison with the
wild-type F strain in ferrets. Moreover, R7 was isolated two years later than R6 and F, which may have
resulted in genetic changes within the HA and NA genes, making the Wt virus F more suitable for
comparison with the OR virus R6.
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Table 1. Aminoacidic sequence comparison of the F and R6 strains. Aminoacidic differences between the two strains. Mutation frequency and the domain into which
they fall were also annotated.
Protein PortionCompared Mutated Position F R6 Frequency Domain Ref.
PB2 1-757 127 Y H 127H 98.8% (1837)
N-terminal-PB1,NP interaction [33]191 K E 191E 97.5% (1812)
221 T A 221A 99.7% (1854)
660 K R 660R 2.5% (47) 627Domain – host range [34]
PB1 1-757 257 T A 257A 0.5% (10) Nucleotide binding site [35]
PB1-F2 1-11 TRUNCATED -
PA 1-716 328 R K 328K 99.8% (1855)
PB1 interaction529 N D 529D 99.8% (1855) [36]
716 K E 716E 0.5% (9)
NP 2-497 400 R K 400K 98.8% (1836) Body [37]
HA 34-349 38 E K 38K 0.1% (1) Fusion HA1 chain [38]
127 L S 127S 99.8% (1860) Receptor binding HA1 chain
NA 188-420 275 H Y 275Y 0.8% (14) Head domain [39]
M1 1-252 -
M2 1-97 -
NS1 1-219 93 M I 93I 2.2% (40) N/A
NS2 1-121 -
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3.7. F-Infected Ferrets Presented More Severe Clinical Signs, and Higher Blood APP and Antibody Responses
than the R6-Infected Group
Control animals did not present clinical signs, an elevation of APP blood levels, or IAV antibody
responses. F-infected ferrets presented a higher percentage of weight loss and clinical scores than
the R6 group (Figure 4A,B), and the weight loss percentage and clinical scores were higher in the F
group than in OR-infected animals at 1 dpi (p < 0.05). At large, no differences in temperature variation
between infected groups were observed (Figure 4C). Two APP, namely SAA and Hp, were analysed
(Figure 4D,E).
1 
 
 
Figure 4. Clinical signs, APP’s levels, and antibody responses in ferrets. (A) Clinical score; (B) percentage of
weight compared with weight at 0 dpi (100%); (C) body temperature; (D) SAA sera levels; (E) haptoglobin
(Hp) sera levels. All values are represented by the mean and SEM ±. Statistically significant differences
are represented by * (p value < 0.05). (F) Antibody response by HI.
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F-infected animals presented increased SAA levels from 1 to 3 dpi. F-infected ferrets showed
higher SAA and Hp levels than R6-infected ferrets at 1 dpi (p < 0.05). Hp serum levels returned to
basal levels at 6 dpi for animals infected with the R6 virus. However, the Hp levels of F virus-infected
ferrets continued to increase until 10 dpi. F-infected ferrets showed higher antibody titers than the R6
group, determined by the haemagglutination inhibition (HI) assay in sera at 0 and 10 dpi (Figure 4F).
3.8. F-Infected Ferrets Showed More Severe Histopathological Lesions and Higher IAV Antigen
Immunostaining than R6-Infected Ferrets
Gross lesions observed in infected animals were rare and subtle. At 1 dpi, one animal infected
with the F virus displayed mild right lung consolidation, while no gross lesions were observed in
R6-infected animals. At 3 dpi, two R6-infected animals displayed mild consolidation of caudal lung
lobes and three ferrets infected with the F virus exhibited generalized interstitial emphysema or
caudal lung consolidation. Animals infected with the F virus presented higher histopathological
scores than R6-infected animals throughout the trial (Figure 5A). No gross or histopathological lesions
were observed in the control group (Figure 5B). Histopathological lesions observed in the lungs of
R6-infected ferrets were consistent with necrotizing bronchiolitis characterized by bronchiolar and
glandular necrosis with lymphoplasmacytic inflammation (Figure 5C). F-infected ferrets exhibited
bronchointerstitial pneumonia with variable grades of extension at 1 and 3 dpi. Diffuse alveolar
damage characterized by high numbers of neutrophilic and macrophagic infiltrates within alveolar
walls and alveolar spaces was also observed in the lungs of two animals infected with the F virus
at 1 dpi (Figure 5D). Two R6-infected ferrets presented with mild bronchointerstitial pneumonia at
1 and 3 dpi. Control animal lungs were negative for IAV antigen expression by ICH. R6-infected ferrets
mainly presented IAV antigen expression on bronchiolar epithelial and glandular cells in bronchiolar
areas (Figure 5E), while F-infected ferrets presented viral antigen expression in bronchiolar and alveolar
areas, with viral antigen expression observed in alveolar pneumocytes and macrophages (Figure 5F).
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Figure 5. Histopathology of lung lesions and viral identification by immunohistochemistry (IHC) in ferrets.
(A) Histopathological scores representing lung lesion severity. Individual values per animal with means
represented by bars; (B) healthy lung in a control animal; (C) necrotizing bronchiolitis in one ferret infected
with the R6 virus; and (D) diffuse alveolar damage in one animal infected with the F virus. (E) IAV-positive
cells located in the bronchiolar epithelium in one animal infected with the R6 virus and (F) IAV-positive
cells by IHC located in the alveolar septa in one ferret infected with the F virus. Images correspond to HE
and immunohistochemical staining for the IAV antigen (20× objective field).
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3.9. F-Infected Ferrets Presented Higher Viral Loads than R6-Infected Ferrets
Viral loads in nasal swabs and lung tissue samples were determined by a plaque assay and
rRT-PCR, respectively (Figure 6). Control animals were negative for viral detection in nasal swabs and
lung tissue samples.
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Figure 6. Viral quantification by PCR and IHC antigen cell accounts in ferrets. (A) Nasal swab viral
shedding. Values represented as PFU/mL. (B) IAV rRT-PCR in the lungs. Values represented as
inverted threshold cycle (Ct) values. (C) Immunohistochemical cell quantification of IAV-positive cells
in bronchiol/bronchiolar areas. (D) Immunohistochemical cell quantification of IAV-positive cells in
alveolar areas. Individual values per animal with means represented by bars.
F-infected animals presented higher viral titers than R6-infected ferrets in nasal swabs at 3 dpi
(Figure 6A). Viral RNA was detected in the lungs of both infected groups (F and R6) at 1 and 3 dpi,
and in the lungs of one R6-infected ferret at 10 dpi. Viral RNA levels were higher in F-infected
ferrets at 1 dpi, but not at 3 dpi, where RNA levels where similar (Figure 6B). Higher numbers of IAV
immune-stained cells were detected at 1 dpi in comparison to 3 dpi in both infected groups. F-infected
animals showed higher numbers of IAV-positive cells in alveolar and bronchiolar areas in comparison
to R6-infected ferrets, particularly at 1 dpi (Figure 6C,D).
3.10. F- and R6-Infected Animals Showed Different Innate Immune Genetic Profiles in the Lungs
throughout Infection
Cytokines, chemokines, and the pattern-recognition receptor (PRR) already known to be related
to IAV infection were quantified by rRT-PCR at 1 and 3 dpi from the lung tissue sampled. The F
group exhibited a higher lung expression of the pro-inflammatory chemokine (C-X-C motif) CXCL10,
IFNγ, and IL-8 at 3 dpi (Figure 7). In addition, higher mRNA levels of IL-6 and IFNγ were detected in
the lungs of F-infected ferrets in comparison to the R6-group, at 1 and 3 dpi. In contrast, lungs from
R6-infected ferrets exhibited a higher induction of the pattern recognition receptor Retinoid acid
Inducible Gene I (RIG-I), type I IFNs (IFNα and IFNβ), and TNFα, at 1 dpi (Figure 7).
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4. Discussion
In general, OR pdm09 viral strains with the H275Y NA mutation are less virulent than Wt
viruses [24,25]. However, several in vivo experiments have found conflicting results regarding their
virulence in mice and ferret models [9,20,40–42]. This study investigated the viral pathogenicity of two
OR pdm09 viral isolates containing the H275Y NA mutation in relation to a Wt pdm09 viral isolate and
assessed the presence of distinctive viral-host immune interactions associated with viral pathogenicity
in each case.
The ability of the OR virus to generate infectious progeny in a host is still controversial.
Despite some studies reporting a statistically significant impairment in viral growth in vitro [9],
other groups’ analysis have not identified significant differences regarding the replicative capacity
between the pdm09 Wt virus and its H275Y variant [43]. Here, different viral kinetics and virulence
were observed between the OR viral strains, with R6 showing higher viral replication capabilities
than the R7 isolate early after infection. In addition, in vitro assessment of the oseltamivir H275Y NA
mutation seems to reduce viral fitness by means of viral replication when compared with the Wt F
virus at the initial stages of infection, as previously described [15,44].
Subsequent to the in vitro study, a comparative study of virus growth fitness and pathogenesis
was performed for R6- and R7-infected mice. The results revealed that both OR strains induced a
fatal outcome, although with different degrees and kinetics. R6-mice experienced a 40% lethality and
R7-mice a 20% lethality at 4 dpi. This result was consistent with the fact that R6 replicated faster in vitro.
Importantly, 50% lethality in F virus-infected mice was only observed when a dose of 106 PFU/mouse
was used in a previous experiment performed by our collaborators [45]. Differences in viral kinetics
were translated into differences in pathogenicity between OR viral strains. Mice belonging to the
R6-infected group showed a statistically significant (p < 0.05) higher percentage of reduction in the body
weight during the first 2 dpi compared to the R7 group of infection, which correlated with more severe
lung histopathological findings of R6-infected mice. Curiously, higher lung viral loads were detected
in R7-infected mice, which may suggest the presence of additional virus-host genetic mechanisms
involved in pathogenicity other than enhanced viral kinetics. However, no statistical differences
were observed within OR-infected groups. Previously, it was reported that the Wt pdm09 virus and
H275Y mutant variant induced comparable mortality rates, weight loss, and lung titers in mice [15].
Our results are partially in agreement with this statement, but we observed dissimilar kinetics in
mortality rates and loss of weight when the two OR viruses were compared. Surprisingly, R6-infected
mice developed higher HA antibody titers than the R7 group, with a strong antibody response at
14 dpi in both infected groups, but the absence of cross-reactive antibodies.
Amino acidic sequences of both viruses were compared, showing that F and R6 viruses exhibited
differences in amino acidic signatures in several proteins, such as PB2, PB1, PA, NP, HA, NA, and NS1.
It is worth mentioning that the majority of signatures of the F virus are rare in the pdm09 linage,
and therefore, a possible correlation with F virus higher pathogenicity in comparison to R6 virus
cannot be excluded. Nevertheless, none of the changes observed in the aminoacidic sequences have
been characterized or described as playing a role in the domains in which they fall [46]. The large
number of mutations found in the F virus polymerase complex indicates that it has been under a strong
selection pressure, even greater than the surface glycoprotein and most probably related to the selected
patient [45].
In relation to seasonal and pdm09 OR virus variants with the same NA mutation, it has been
proposed that they might differ in replication or transmission fitness, depending on other viral
components [47]. Previous studies have highlighted that a particular combination of residues in
seasonal and pdm09 viruses, such as V234M or R222Q, which were not observed in earlier H1N1
viruses, resulted in an increased affinity of the NA cleavage balance. Moreover, those mutations
were also significantly beneficial in compensating for the deleterious effect of the OR mutation [14,48].
Interestingly, it has been shown that viruses from both the Newcastle and Sapporo clusters contained
permissive NA mutations V241I and N369K that enhance the replication and transmission fitness
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of viruses containing the H275Y mutation [49]. In addition, there is an increasing body of evidence
that the NA275 mutation alone does not confer complete oseltamivir resistance in vivo, despite being
repeatedly described in OR viral isolates, which may indicate that oseltamivir resistance mutations
also exert effects in a genetic host-specific manner [50], in accordance with the results observed in this
study. Therefore, the slower viral replication observed at early stages of infection in the R6 virus might
be due to the lack of compensating mutations compared to the F group, but similar viral kinetics at
later time points, further pointing to genetic host-specific interactions during early infection phases as
being relevant in the pathogenicity of the virus beyond later viral replication capacities.
More severe histopathologic lesions were apparent throughout the infection in ferrets belonging
to the Wt pdm09 group, and more severe lesion scores were associated with increased in situ release
of pro-inflammatory cytokines in the lungs and higher levels of acute phase proteins in the serum.
In comparison with these results, F-infected animals exhibited significantly higher clinical scores
compared to their OR counterparts. Several studies on ferrets and other mammals have already
concluded that an elevated viral replication burden in the lungs and increased levels of APP are related
to severe influenza virus infection [28,51,52].
The lung immune response in ferrets presented high individual variability within groups and
no statistically significant results were observed between infection groups. However, F-infected
ferrets showed a pattern characterized by a higher induction of pro-inflammatory cytokines IL-6,
IL-8, CXCL10, TNFα, and IFNγ, particularly at 3 dpi. It has previously been described that the presence
of a viral antigen in alveolar areas, together with the up-regulation of pro-inflammatory cytokines, is a
marker of severity during pdm09 infection, both in humans and animal models [32,53,54]. Therefore, it is
conceivable to suggest that lung lesions and clinical signs observed in F-infected animals might be, in part,
a consequence of the lung’s excessive pro-inflammatory response as a result of the spread of the virus to
alveolar areas.
These results support previous studies which have hypothesized that OR-hampered virus growth
in vitro may be a result of a reduced NA enzyme efficiency, which delays the release of progeny
virions from the host cell surface. This delay would probably not affect the final virus exert, but would
allow the host’s first-line innate immune defense to neutralize the virus in in vivo experiments [9].
Several studies have indicated that the correct and specific regulation of the innate immune response
dynamics, particularly the up-regulation of IFN type I genes, are protective factors in the pathological
outcome after pdm09 infection [32,55–57]. In agreement, our study showed that R6-infected ferrets
presented a higher expression of interferon I and RIG-I genes, which was correlated with a lower
viral load at 1 dpi. These observations could indicate that the host innate immune response better
identified the R6 virus due to the slower viral growth at the early stages. In this context, such slower
viral growth would allow the host to limit viral infection to bronchiolar areas, as shown by IAN antigen
immunostaining in the lungs, avoiding the release of detrimental pro-inflammatory cytokines and
resulting alveolar damage.
Overall, the present study provides further evidence about the important role of an efficient early innate
immune response in the outcome of disease after influenza virus infection. Therefore, understanding the
interaction among both viral genetic features inside the host immune genetic context is required for
the development of future therapies against IAV infection.
Author Contributions: Conceptualization, M.M., L.F. and N.M.; methodology, M.M., J.M., J.M.M., N.M., L.F.;
software, B.V., L.F.; validation, L.F., M.M. and L.M.-G.; formal analysis, L.F.; investigation, B.V., P.M.-O., M.B., J.M.M.,
L.M.-G., L.C., M.P.; resources, I.C., F.P.; data curation, M.M., B.V., P.M.-O. and L.F.; writing—original draft preparation,
B.V., P.M.-O., L.F., J.M.M., L.M.-G.; writing—review and editing, M.M.; supervision, M.M.; project administration,
M.M.; funding acquisition, M.M. All authors have read and agreed to the published version of the manuscript.
Funding: This work was funded by the coordinated project RTA 2011-00111-C03 of the Instituto Nacional de
Investigación y Tecnología Agraria y Alimentaria (INIA), by Instituto de Salud Carlos III (“Programa especial de
investigación sobre la gripe pandémica” GR09/0023, GR09/0040, GR09/0039), and by the Servei de Diagnòstic de
Patologia Veterinària (SDPV) of the Universitat Autònoma de Barcelona. This work was also partially funded by
the CERCA program from Generalitat de Catalunya.
Viruses 2020, 12, 794 17 of 20
Acknowledgments: The authors are grateful to Amelia Nieto for providing the sequences for the F virus and to
the BSL3 facility staff for the technical support they provided during the experimental infection period.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Donaldson, L.J.; Rutter, P.D.; Ellis, B.M.; Greaves, F.E.; Mytton, O.T.; Pebody, R.G.; Yardley, I.E. Mortality from
pandemic A/H1N1 2009 influenza in England: Public health surveillance study. BMJ 2009, 339, b5213.
[CrossRef] [PubMed]
2. Smith, G.J.; Vijaykrishna, D.; Bahl, J.; Lycett, S.J.; Worobey, M.; Pybus, O.G.; Ma, S.K.; Cheung, C.L.;
Raghwani, J.; Bhatt, S.; et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A
epidemic. Nature 2009, 459, 1122–1125. [CrossRef] [PubMed]
3. Krumbholz, A.; Schmidtke, M.; Bergmann, S.; Motzke, S.; Bauer, K.; Stech, J.; Durrwald, R.; Wutzler, P.;
Zell, R. High prevalence of amantadine resistance among circulating European porcine influenza A viruses.
J. Gen. Virol. 2009, 90, 900–908. [CrossRef]
4. Dawood, F.S.; Jain, S.; Finelli, L.; Shaw, M.W.; Lindstrom, S.; Garten, R.J.; Gubareva, L.V.; Xu, X.; Bridges, C.B.;
Uyeki, T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med.
2009, 360, 2605–2615.
5. Zambon, M.; Hayden, F.G. Position statement: Global neuraminidase inhibitor susceptibility network.
Antivir. Res. 2001, 49, 147–156. [CrossRef]
6. Kiso, M.; Shinya, K.; Shimojima, M.; Takano, R.; Takahashi, K.; Katsura, H.; Kakugawa, S.; Le, M.T.;
Yamashita, M.; Furuta, Y.; et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A
viruses. PLoS Pathog. 2010, 6, e1001079. [CrossRef] [PubMed]
7. Yi, H.; Lee, J.Y.; Hong, E.H.; Kim, M.S.; Kwon, D.; Choi, J.H.; Choi, W.Y.; Kim, K.S.; Lee, J.K.; Oh, H.B.; et al.
Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. Emerg. Infect. Dis. 2010, 16, 1938–1942.
[CrossRef]
8. Huang, W.; Li, X.; Cheng, Y.; Tan, M.; Guo, J.; Wei, H.; Zhao, X.; Lan, Y.; Xiao, N.; Wang, Z.; et al. Characteristics
of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013–2014 influenza season in Mainland
China. Virol. J. 2015, 12, 96. [CrossRef]
9. Duan, S.; Boltz, D.A.; Seiler, P.; Li, J.; Bragstad, K.; Nielsen, L.P.; Webby, R.J.; Webster, R.G.; Govorkova, E.A.
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in
ferrets. PLoS Pathog. 2010, 6, e1001022. [CrossRef]
10. Hurt, A.C. The epidemiology and spread of drug resistant human influenza viruses. Curr. Opin. Virol.
2014, 8C, 22–29. [CrossRef] [PubMed]
11. Herlocher, M.L.; Truscon, R.; Elias, S.; Yen, H.L.; Roberts, N.A.; Ohmit, S.E.; Monto, A.S. Influenza viruses
resistant to the antiviral drug oseltamivir: Transmission studies in ferrets. J. Infect. Dis. 2004, 190, 1627–1630.
[CrossRef] [PubMed]
12. Ives, J.A.; Carr, J.A.; Mendel, D.B.; Tai, C.Y.; Lambkin, R.; Kelly, L.; Oxford, J.S.; Hayden, F.G.; Roberts, N.A.
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate
treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 2002, 55, 307–317.
[CrossRef]
13. Moscona, A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360, 953–956.
[CrossRef] [PubMed]
14. Bloom, J.D.; Gong, L.I.; Baltimore, D. Permissive secondary mutations enable the evolution of influenza
oseltamivir resistance. Science 2010, 328, 1272–1275. [CrossRef]
15. Abed, Y.; Pizzorno, A.; Bouhy, X.; Rheaume, C.; Boivin, G. Impact of potential permissive neuraminidase
mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice
and in ferrets. J. Virol. 2014, 88, 1652–1658. [CrossRef]
16. Bloom, J.D.; Nayak, J.S.; Baltimore, D. A computational-experimental approach identifies mutations that
enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 2011, 6, e22201.
[CrossRef]
Viruses 2020, 12, 794 18 of 20
17. Hurt, A.C.; Chotpitayasunondh, T.; Cox, N.J.; Daniels, R.; Fry, A.M.; Gubareva, L.V.; Hayden, F.G.; Hui, D.S.;
Hungnes, O.; Lackenby, A.; et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic:
Public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 2012, 12, 240–248. [CrossRef]
18. Van der Vries, E.; Stittelaar, K.J.; van Amerongen, G.; Veldhuis Kroeze, E.J.; de Waal, L.; Fraaij, P.L.;
Meesters, R.J.; Luider, T.M.; van der Nagel, B.; Koch, B.; et al. Prolonged influenza virus shedding and
emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 2013, 9, e1003343.
[CrossRef]
19. Dunning, J.; Baillie, J.K.; Cao, B.; Hayden, F.G. Antiviral combinations for severe influenza. Lancet Infect. Dis.
2014, 14, 1259–1270. [CrossRef]
20. Hurt, A.C.; Hardie, K.; Wilson, N.J.; Deng, Y.M.; Osbourn, M.; Leang, S.K.; Lee, R.T.; Iannello, P.;
Gehrig, N.; Shaw, R.; et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant
A(H1N1)pdm09 influenza in Australia. J. Infect. Dis. 2012, 206, 148–157. [CrossRef]
21. Takashita, E.; Ejima, M.; Itoh, R.; Miura, M.; Ohnishi, A.; Nishimura, H.; Odagiri, T.; Tashiro, M. A community
cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan,
November to December 2013. Euro. Surveill 2014, 19. [CrossRef] [PubMed]
22. Takashita, E.; Kiso, M.; Fujisaki, S.; Yokoyama, M.; Nakamura, K.; Shirakura, M.; Sato, H.; Odagiri, T.; Kawaoka, Y.;
Tashiro, M. Characterization of a large cluster of influenza A (H1N1) pdm09 viruses cross-resistant to oseltamivir
and peramivir during the 2013–2014 influenza season in Japan. Antimicrob. Agents Chemother. 2015, 59, 2607–2617.
[CrossRef] [PubMed]
23. Kossyvakis, A.; Mentis, A.A.; Tryfinopoulou, K.; Pogka, V.; Kalliaropoulos, A.; Antalis, E.; Lytras, T.; Meijer, A.;
Tsiodras, S.; Karakitsos, P.; et al. Antiviral susceptibility profile of influenza A viruses; keep an eye on
immunocompromised patients under prolonged treatment. Eur. J. Clin. Microbiol. Infect. Dis 2017, 36, 361–371.
[CrossRef] [PubMed]
24. Leang, S.K.; Deng, Y.M.; Shaw, R.; Caldwell, N.; Iannello, P.; Komadina, N.; Buchy, P.; Chittaganpitch, M.;
Dwyer, D.E.; Fagan, P.; et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antivir. Res.
2013, 97, 206–210. [CrossRef] [PubMed]
25. Okomo-Adhiambo, M.; Nguyen, H.T.; Abd Elal, A.; Sleeman, K.; Fry, A.M.; Gubareva, L.V. Drug susceptibility
surveillance of influenza viruses circulating in the United States in 2011–2012: Application of the WHO
antiviral working group criteria. Influenza Other Respir. Viruses 2013, 8, 258–265. [CrossRef] [PubMed]
26. Bragstad, K.; Hungnes, O.; Litleskare, I.; Nyrerod, H.C.; Dorenberg, D.H.; Hauge, S.H. Community spread
and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
Influenza Other Respir. Viruses 2019, 13, 372–381. [CrossRef] [PubMed]
27. Hashem, A.M.; Azhar, E.I.; Shalhoub, S.; Abujamel, T.S.; Othman, N.A.; Al Zahrani, A.B.; Abdullah, H.M.;
Al-Alawi, M.M.; Sindi, A.A. Genetic characterization and diversity of circulating influenza A/H1N1pdm09
viruses isolated in Jeddah, Saudi Arabia between 2014 and 2015. Arch. Virol. 2018, 163, 1219–1230. [CrossRef]
28. Martinez-Orellana, P.; Martorell, J.; Vidana, B.; Majo, N.; Martinez, J.; Falcon, A.; Rodriguez-Frandsen, A.;
Casas, I.; Pozo, F.; Garcia-Migura, L.; et al. Clinical response to pandemic h1n1 influenza virus from a fatal
and mild case in ferrets. Virol. J. 2015, 12, 48. [CrossRef]
29. Reed, L.J.; Muench, H. A simple method of estimating fifty per cent endpoint. Am. J. Hyg. 1938, 27, 493–497.
30. Almansa, R.; Martinez-Orellana, P.; Rico, L.; Iglesias, V.; Ortega, A.; Vidana, B.; Martinez, J.; Exposito, A.;
Montoya, M.; Bermejo-Martin, J.F. Pulmonary transcriptomic responses indicate a dual role of inflammation in
pneumonia development and viral clearance during 2009 pandemic influenza infection. PeerJ 2017, 5, e3915.
[CrossRef]
31. Busquets, N.; Segales, J.; Cordoba, L.; Mussa, T.; Crisci, E.; Martin-Valls, G.E.; Simon-Grife, M.; Perez-Simo, M.;
Perez-Maillo, M.; Nunez, J.I.; et al. Experimental infection with H1N1 European swine influenza virus
protects pigs from an infection with the 2009 pandemic H1N1 human influenza virus. Vet. Res. 2010, 41, 74.
[CrossRef] [PubMed]
32. Vidana, B.; Martinez, J.; Martinez-Orellana, P.; Garcia Migura, L.; Montoya, M.; Martorell, J.; Majo, N.
Heterogeneous pathological outcomes after experimental pH1N1 influenza infection in ferrets correlate with
viral replication and host immune responses in the lung. Vet. Res. 2014, 45, 85. [CrossRef]
33. Poole, E.; Elton, D.; Medcalf, L.; Digard, P. Functional domains of the influenza A virus PB2 protein:
Identification of NP- and PB1-binding sites. Virology 2004, 321, 120–133. [CrossRef] [PubMed]
Viruses 2020, 12, 794 19 of 20
34. Tarendeau, F.; Crepin, T.; Guilligay, D.; Ruigrok, R.W.; Cusack, S.; Hart, D.J. Host determinant residue lysine
627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. PLoS Pathog.
2008, 4, e1000136. [CrossRef] [PubMed]
35. Asano, Y.; Ishihama, A. Identification of two nucleotide-binding domains on the PB1 subunit of influenza
virus RNA polymerase. J. Biochem. 1997, 122, 627–634. [CrossRef]
36. Guu, T.S.; Dong, L.; Wittung-Stafshede, P.; Tao, Y.J. Mapping the domain structure of the influenza A
virus polymerase acidic protein (PA) and its interaction with the basic protein 1 (PB1) subunit. Virology
2008, 379, 135–142. [CrossRef]
37. Ye, Q.; Krug, R.M.; Tao, Y.J. The mechanism by which influenza A virus nucleoprotein forms oligomers and
binds RNA. Nature 2006, 444, 1078–1082. [CrossRef]
38. Sriwilaijaroen, N.; Suzuki, Y. Molecular basis of the structure and function of H1 hemagglutinin of influenza
virus. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2012, 88, 226–249. [CrossRef]
39. Shtyrya, Y.A.; Mochalova, L.V.; Bovin, N.V. Influenza virus neuraminidase: Structure and function. Acta Nat.
2009, 1, 26–32. [CrossRef]
40. Hamelin, M.E.; Baz, M.; Abed, Y.; Couture, C.; Joubert, P.; Beaulieu, E.; Bellerose, N.; Plante, M.; Mallett, C.;
Schumer, G.; et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart
in mice and ferrets. PLoS Pathog. 2010, 6, e1001015. [CrossRef]
41. Kwon, D.; Shin, K.; Kim, S.J.; Lee, J.Y.; Kang, C. Mammalian pathogenesis of oseltamivir-resistant pandemic
(H1N1) 2009 influenza virus isolated in South Korea. Virus Res. 2014, 185, 41–46. [CrossRef] [PubMed]
42. Memoli, M.J.; Davis, A.S.; Proudfoot, K.; Chertow, D.S.; Hrabal, R.J.; Bristol, T.; Taubenberger, J.K.
Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in
ferrets. J. Infect. Dis. 2010, 203, 348–357. [CrossRef] [PubMed]
43. Seibert, C.W.; Kaminski, M.; Philipp, J.; Rubbenstroth, D.; Albrecht, R.A.; Schwalm, F.; Stertz, S.; Medina, R.A.;
Kochs, G.; Garcia-Sastre, A.; et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A
virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 2010, 84, 11219–11226.
[CrossRef] [PubMed]
44. Baz, M.; Abed, Y.; Simon, P.; Hamelin, M.E.; Boivin, G. Effect of the neuraminidase mutation H274Y conferring
resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1)
viruses. J. Infect. Dis. 2010, 201, 740–745. [CrossRef]
45. Rodriguez, A.; Falcon, A.; Cuevas, M.T.; Pozo, F.; Guerra, S.; Garcia-Barreno, B.; Martinez-Orellana, P.;
Perez-Brena, P.; Montoya, M.; Melero, J.A.; et al. Characterization in vitro and in vivo of a pandemic H1N1
influenza virus from a fatal case. PLoS ONE 2013, 8, e53515. [CrossRef]
46. Goka, E.A.; Vallely, P.J.; Mutton, K.J.; Klapper, P.E. Mutations associated with severity of the pandemic
influenza A(H1N1)pdm09 in humans: A systematic review and meta-analysis of epidemiological evidence.
Arch. Virol. 2014, 159, 3167–3183. [CrossRef]
47. Hurt, A.C.; Nor’e, S.S.; McCaw, J.M.; Fryer, H.R.; Mosse, J.; McLean, A.R.; Barr, I.G. Assessing the viral fitness of
oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 2010, 84, 9427–9438.
[CrossRef]
48. Renzette, N.; Caffrey, D.R.; Zeldovich, K.B.; Liu, P.; Gallagher, G.R.; Aiello, D.; Porter, A.J.; Kurt-Jones, E.A.;
Bolon, D.N.; Poh, Y.P.; et al. Evolution of the influenza A virus genome during development of oseltamivir
resistance in vitro. J. Virol. 2014, 88, 272–281. [CrossRef]
49. Butler, J.; Hooper, K.A.; Petrie, S.; Lee, R.; Maurer-Stroh, S.; Reh, L.; Guarnaccia, T.; Baas, C.; Xue, L.;
Vitesnik, S.; et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in
recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014, 10, e1004065. [CrossRef]
50. Duan, S.; Govorkova, E.A.; Bahl, J.; Zaraket, H.; Baranovich, T.; Seiler, P.; Prevost, K.; Webster, R.G.; Webby, R.J.
Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant
H1N1 influenza viruses. Nat. Commun. 2014, 5, 5029. [CrossRef]
51. Van den Brand, J.M.; Stittelaar, K.J.; van Amerongen, G.; Reperant, L.; de Waal, L.; Osterhaus, A.D.; Kuiken, T.
Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic
avian influenza H5N1 virus infections in ferrets. PLoS ONE 2012, 7, e42343. [CrossRef] [PubMed]
52. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med.
1999, 340, 448–454. [CrossRef] [PubMed]
Viruses 2020, 12, 794 20 of 20
53. Keynan, Y.; Malik, S.; Fowke, K.R. The role of polymorphisms in host immune genes in determining the
severity of respiratory illness caused by pandemic H1N1 influenza. Public Health Genom. 2013, 16, 9–16.
[CrossRef] [PubMed]
54. Mauad, T.; Hajjar, L.A.; Callegari, G.D.; da Silva, L.F.; Schout, D.; Galas, F.R.; Alves, V.A.; Malheiros, D.M.;
Auler, J.O., Jr.; Ferreira, A.F.; et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am. J.
Respir. Crit. Care Med. 2010, 181, 72–79. [CrossRef]
55. Brandes, M.; Klauschen, F.; Kuchen, S.; Germain, R.N. A systems analysis identifies a feedforward
inflammatory circuit leading to lethal influenza infection. Cell 2013, 154, 197–212. [CrossRef]
56. Huang, Y.; Zhu, W.; Zeng, X.; Li, S.; Li, X.; Lu, C. Innate and adaptive immune responses in patients with
pandemic influenza A(H1N1)pdm09. Arch. Virol. 2013, 158, 2267–2272. [CrossRef]
57. Vidana, B.; Martinez, J.; Martorell, J.; Montoya, M.; Cordoba, L.; Perez, M.; Majo, N. Involvement of the
different lung compartments in the pathogenesis of pH1N1 influenza virus infection in ferrets. Vet. Res.
2016, 47, 113. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
